Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | PTPRF | P10586 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794528 | 1.00 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2ANPC1TP53 | |
| SCHEMBL2797012 | 1.00 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2ANPC1TP53 | |
| SCHEMBL19505660 | 0.86 | SIGMAR1 (0.69) | SIGMAR1MEN1KMT2ANPC1TP53 | |
| Methamphetamine SCHEMBL9114817 | 0.84 | MEN1 (0.65) | SIGMAR1MEN1KMT2ANPC1TP53 | |
| SCHEMBL19505485 | 0.83 | SIGMAR1 (0.71) | SIGMAR1MEN1KMT2A | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CYP2D6CYP1A2LMNACYP3A4 | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CYP2D6CYP1A2LMNACYP3A4 | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CYP2D6CYP1A2LMNACYP3A4 | |
| SCHEMBL6238634 | 0.81 | ALDH1A1 (0.51) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23754496 | 0.81 | SMN1; SMN2 (0.60) | MEN1KMT2ASMN1; SMN2PTPRFPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-04-14 | — | — | US | disclosed |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The USA, as represented by the Secretary, Departme nt of Health and Human Services (US) | 2019-01-10 | — | — | US | disclosed |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| EP-2544676-B1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | US HEALTH (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-05-24 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011112867-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| EP-2064174-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007005845-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885MEN1 4799/4885KMT2A 4127/4885 |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SIGMAR1 1095/4885MEN1 3464/4885KMT2A 489/4885 |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885MEN1 4799/4885KMT2A 4127/4885 |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SIGMAR1 1095/4885MEN1 3464/4885KMT2A 489/4885 |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 332/4885MEN1 4775/4885KMT2A 4171/4885 |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885MEN1 4799/4885KMT2A 4127/4885 |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885MEN1 4799/4885KMT2A 4127/4885 |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885MEN1 1082/4885KMT2A 3251/4885 |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 364/4885MEN1 1120/4885KMT2A 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.